Literature DB >> 3409947

Effect of low-dose doxorubicin on calcium content and norepinephrine response in rat aorta.

H F Dalske1, K Hardy.   

Abstract

Doxorubicin (DXR) is a common antineoplastic agent whose clinical utility is limited by development of a dose-related cardiomyopathy. Recent studies demonstrating DXR toxicity in skeletal muscle suggest that this compound may in fact be a general depressant of muscle function. Although previous studies have reported possible indirect actions of DXR on blood vessels, we have investigated the direct effects of this agent on vascular smooth muscle. Chronic, low-dose treatment of rats with intraperitoneal DXR (12 mg/kg total dose over 4 weeks) had no significant effect on body or heart weight, left ventricular water or calcium content, or aortic water or calcium content. Contractile responses to norepinephrine of thoracic aortic strips taken from DXR-treated rats were attenuated by this treatment, and sensitivity (EC50) of these strips to norepinephrine was significantly reduced compared to controls. These results suggest that DXR may have physiological effects on vascular smooth muscle function at doses which produce no signs of toxicity in cardiac muscle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409947     DOI: 10.1016/0277-5379(88)90146-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Chronic vascular toxicity of doxorubicin in an organ-cultured artery.

Authors:  T Murata; H Yamawaki; M Hori; K Sato; H Ozaki; H Karaki
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Doxorubicin-induced vasomotion and [Ca(2+)](i) elevation in vascular smooth muscle cells from C57BL/6 mice.

Authors:  Bing Shen; Chun-ling Ye; Kai-he Ye; Lan Zhuang; Jia-hua Jiang
Journal:  Acta Pharmacol Sin       Date:  2009-10-12       Impact factor: 6.150

3.  Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats.

Authors:  Jae-Sun Uhm; Woo-Baek Chung; Jung-Sook Yoon; Yong-Seog Oh; Ho-Joong Youn
Journal:  Clin Hypertens       Date:  2014-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.